Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline BRCA1 Gene Mutation”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Not applicableUnknownNCT04983628
What this trial is testing

Molecular Profiling in Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticProstate Cancer RecurrentGermline BRCA1 Gene Mutation+2 more
Hellenic Cooperative Oncology Group 250
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT04089189
What this trial is testing

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Who this might be right for
Ovarian Cancer
Impact Therapeutics, Inc. 93
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Not applicableStudy completedNCT00582803
What this trial is testing

Adherence to Intensive Surveillance for Hereditary Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 85
Not applicableLooking for participantsNCT05769517
What this trial is testing

PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

Who this might be right for
BRCA MutationOvarian CancerUltrasound Therapy; Complications
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,300
Not applicableStudy completedNCT04683068
What this trial is testing

Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing

Who this might be right for
BRCA1 MutationBRCA2 MutationPsychosocial Factors
European Institute of Oncology 264
Not applicableLooking for participantsNCT07292246
What this trial is testing

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

Who this might be right for
Breast CancerBRCA 1 Gene MutationBRCA 2 Gene Mutation+5 more
Vasileios Kalles 15
Not applicableEnded earlyNCT04668521
What this trial is testing

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Who this might be right for
Adnexal MassGermline BRCA1 Gene MutationGermline BRCA2 Gene Mutation+1 more
Aspira Women's Health 215
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT01670500
What this trial is testing

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

Who this might be right for
Breast Cancer
Beth Israel Deaconess Medical Center 118
Large-scale testing (Phase 3)UnknownNCT04296370
What this trial is testing

Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Who this might be right for
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd. 474
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Not applicableStudy completedNCT02557776
What this trial is testing

Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer

Who this might be right for
Hereditary Breast Cancer
Lund University 542
Load More Results